IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Response to Questions Re: USTR 2023 Special 301 Review
IPO Comments to CNIPA on Draft Amendment to the Trademark [...]
Software and Medical Device Guidance: A Global Perspective
IPO’s Comments on the Draft 2022-2026 USPTO Strategic Plan
IPO Comments on Joint USPTO–FDA Collaboration Initiatives
IPO Comments Regarding USPTO Initiatives To Ensure the Robustness and [...]
IPO Comments Regarding Expanding Opportunities to Appear Before the Patent [...]
IPO Comments Regarding Expanding Admission Criteria for Registration to Practice [...]
IPO 2023 Special 301 Review Comments
IPO Amicus Brief in Jack Daniel's Properties, Inc. v. VIP [...]